METHOD FOR PREDICTING TARGETED THERAPY EFFECTIVENESS IN PATIENTS WITH LIGHT CELL KIDNEY CANCER Russian patent published in 2021 - IPC G01N33/49 A61K31/404 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: invention relates to medicine, namely to oncology, it can be used for estimating the targeted therapy effectiveness when treating patients with light cell kidney cancer, as well as monitoring of treatment of this oncological disease. The level of matrix metalloproteinase 9 (hereinafter – MMP9) in blood serum and tumor M2–pyruvate kinase (hereinafter – Tu M2–PK) in EDTA plasma is determined by immunoassay analysis before treatment and against the background of the first 2-3 cycles of the targeted therapy. If a simultaneous increase in MMP9 by at least 1.4 times and a decrease in the level of Tu M2-PK by at least 2 times are detected, then regression of tumor foci is predicted during the targeted therapy. Studies of blood serum and plasma are carried out every 6 weeks against the background of the targeted therapy.

EFFECT: use of the invention makes it possible to increase the accuracy of the prediction of the targeted therapy effectiveness in patients with light cell kidney cancer, to reduce the time for obtaining the prediction, to clarify the prediction at the stages of treatment.

2 cl, 3 ex